Comparative Pharmacology
Head-to-head clinical analysis: JENLOGA versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENLOGA versus WOLFINA.
JENLOGA vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
Not specified in available data; likely unapproved or investigational drug.
350 mg orally once daily with food.
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive